China Blood Product Industry Report, 2020-2027

Mar.2021

ResearchInChina
www.researchinchina.com

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which has further opened up the blood product market. In 2020, the lot release volume of blood products in China sustained growth, hitting 101.31 million bottles, a year-on-year upsurge of 12.7%.

Wherein, the lot release volume of human albumin rose 14.78% on an annualized basis, making up 60%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 12.92% in the total showed a year-on-year increase of 11.78%; that of human tetanus immunoglobulin soared by 76.7% and accounted for 6.9%; other products like human fibrinogen, human prothrombin complex and human coagulation factor VIII took relatively low shares.

Structure of Blood Products in China (by Lot Release Volume), 2020



Source: National Institutes for Food and Drug Control and 8 Local Institutes for Drug Control; ResearchInChina

The Health Commission of Yunnan Province proposed to set up 24 plasma collection stations (adding 20 new ones based on the 4 pilot ones) across the province, according to the Plan of Yunnan Province for Setting up Plasma Collection Stations (2020-2023) (Exposure Draft) it issued in December 2020. Currently, Shanghai Blood Products under Beijing Tiantan Biological Products has 2 pilot stations operated in Yunnan, having collected a total of around 42 tons. Also, the document indicates blood product companies that construct production bases in Yunnan will be given priority to build. With its plasma station expansion plan, Yunnan may set the pace in loosening the restrictions on new plasma stations. On one estimate, China had boasted 273 plasma collection stations by the end of 2020.

In 2020, the pandemic suspended plasma collection in China for two months, stopping collection volume growth. Chinese Academy of Medical Sciences predicted a like-on-like slump of 22%, or 1,000 tons, in plasma collection volume in the first half of 2020.

Companies with more plasma stations, such as Beijing Tiantan Biological Products, Shanghai RAAS Blood Products, China Biologic Products and Hualan Biological Engineering gather pace and will scramble for larger shares on the strength of their great ability to collect plasma, promising their far higher industry status. In 2019, Beijing Tiantan Biological Products, Hualan Biological Engineering, China Biologic Products and Shanghai RAAS Blood Products took a higher combined market share of up to 34.47%.

Plasma Collection Volume Structure of Major Companies in China, 2019



Source: ResearchInChina

In recent years, there were an increasing number of mergers and acquisitions among blood products companies in China. Leaders roared ahead mainly by way of mergers and acquisitions, an expansion model supplemented by self-built plasma stations. Mergers and acquisitions have been a key part of their long-term strategic plans.

On January 28, 2020, Southern Shuanglin Bio-Pharmacy made an announcement that it would merge with Harbin Pacific Biopharmaceutical and restructure it, and raise funds. Southern Shuanglin Bio-Pharmacy now has 13 plasma collection stations, collecting roughly 400 tons in 2019, compared with Harbin Pacific Biopharmaceutical which owns 10 stations collecting 240 tons in 2019. Moreover, Southern Shuanglin Bio-Pharmacy and Xinjiang Deyuan Bioengineering forged a strategic partnership in which Xinjiang Deyuan Bioengineering promises to provide over 180-ton plasma for Southern Shuanglin Bio-Pharmacy every year, totaling more than 900 tons for the five years to come. Southern Shuanglin Bio-Pharmacy is thus expected to be a first-echelon player in the industry.

China Blood Product Industry Report, 2020-2027 highlights the following:

◆ China blood product industry (policy, status quo, market structure, supply & demand, market size, competitive pattern);
◆ China blood product market segments (status quo, bid price, competitive pattern);
◆ 13 blood product companies (operation, revenue structure, gross margin, blood product business, etc.);
◆ Summary and forecast.

Table of contents

Table of contents

Table of contents

Room 2-626, 6th Floor, No.1, Shanyuan Street, Haidian District, Beijing, 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Selected Charts

Selected Charts

Main Products of Major Blood Product Producers in China
Revenue of Major Blood Product Enterprises in China, 2013-2020
Net Income of Major Blood Product Enterprises in China, 2013-2020
Revenue from Blood Products Business of Major Blood Product Enterprises in China, 2013-2020
Market Share of China Blood Product Industry (by Enterprise), 2018
Market Share of China Blood Product Industry (by Enterprise), 2019
Lot Release Volume and YoY Growth of Human Albumin in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Albumin, 2019
Average Successful Bid Prices for Human Albumin in China, 2017-2020
Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2020
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2018
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2019
Lot Release Volume Structure of Human Albumin in China (by Enterprise), 2020
Major Enterprises' Deployments in Recombinant Human Albumin in China
Lot Release Volume of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Human Immunoglobulin (pH4) for Intravenous Injection, 2019
Average Successful Bid Prices for Human Immunoglobulin (pH4) for Intravenous Injection in China, 2016-2020
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2018
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2019
Lot Release Volume Structure of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Enterprise), 2020
Comparison between China and the United States in Per Capita Consumption of Human Albumin and Human Immunoglobulin (pH4) for Intravenous Injection
Lot Release Volume and YoY Growth of Blood Coagulation Factor VIII in China, 2010-2020
Average Successful Bid Prices Offered by Major Blood Product Enterprises in China for Coagulation Factor VIII, 2019

Selected Charts

Room 2-626, 6th Floor, No.1, Shanyuan Street, Haidian District, Beijing, 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Selected Charts

Selected Charts

Selected Charts

Room 2-626, 6th Floor, No.1, Shanyuan Street, Haidian District, Beijing, 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Selected Charts

Selected Charts

How to Buy

You can place your order in the following alternative ways:

1.Order online at www.researchinchina.com

2.Fax order sheet to us at fax number:+86 10 82601570

3. Email your order to: report@researchinchina.com

4. Phone us at +86 10 82600828

Choose type of format

PDF (Single user license) …………..3,400 USD

Hard copy ………………….……. 3,600 USD

PDF (Enterprisewide license)…....... 5,000 USD

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 2-626, 6th Floor, No.1, Shanyuan Street, Haidian District, Beijing, 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No # : 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
Total		

※ Reports will be dispatched immediately once full payment has been received. Payment may be made by wire transfer or credit card via PayPal.

ResearchInChina
www.researchinchina.com